에 대한 최신 뉴스 Birkenstock Holding (NYSE:BIRK) 주식

Birkenstock Holding

Birkenstock Holding PLC is a company that manufactures and sells footbed-based products, including sandals, closed-toe silhouettes, and other products, such as skincare and accessories, for everyday, leisure, and work. It sells its products through two main channels: business-to-business (B2B) which comprises sales made to established third-party store networks, and direct-to-consumer (DTC) which comprises sales made on globally owned online stores through the Birkenstock.com domain and sales made in Birkenstock retail stores. The company's reportable segments are based on its regional hubs and include: the Americas which is also its key revenue-generating segment; Europe; and Australia, Japan, India, China, and the United Arab Emirates (APMA).

Large Cap

News

Movers

Trading Ideas

BIRK

CHWY

DOCS

KVYO

NBIX

TEVA

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 테바 파마수티컬스(NYSE:TEVA)의 주식은 회사와 사노피 SA(NASDAQ:SNY)가 궤양성 대장염 및 크론병에 대한 두바키투그(Duvakitug)의 2b상 시험에서 1차 평가변수가 충족되었다고 발표한 후 주가는 33.88% 상승했다.

테바, 리 오토 및 다덴 레스토랑이 지난주 최고 성과를 보여준 10개 대형주 중 일부 (12월 16-20일)

APTV

BGNE

MRNA

POOL

이들 10개 대형주는 지난 주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 월그린스 부츠 얼라이언스(NASDAQ:WBA)의 주가는 회사가 혼합된 3분기 실적을 보고하고 2024년 지침을 컨센서스 추정치보다 낮게 낮춘 후 24.12% 하락했다. 분석가들은 주식에 대한 가격 예측을 하향 조정했다.

모더나와 월그린스는 지난주 최악의 성과를 보인 10대 대형주 중 일부 (6월 23일-6월 29일)

General

BURL

CAVA

New Oriental Education & Technology Group

ONON

지난주 이들 10개의 대형주는 최고의 성과를 거두었다. 이들 주식이 당신의 포트폴리오에 있나요? 버켄스탁 홀딩(NYSE:BIRK)의 주가는 회사가 강력한 2분기 실적을 발표하고 연간 매출 성장 가이던스를 상향 조정한 후 22.20% 상승했다. 몇몇 애널리스트들은 목표 주가를 상향 조정했다. 

니오와 베스트 바이는 지난주 최고의 성과를 보인 10개의 대형주 중 일부

Birkenstock Holding PLC

Birks Group Inc

<a href="https://www.bseindia.com/xml-data/corpfiling/AttachLive/79ff5f5f-81a0-4bb0-a2f0-b93541f1164e.pdf" title="https://www.bseindia.com/xml-data/corpfiling/AttachLive/79ff5f5f-81a0-4bb0-a2f0-b93541f1164e.pdf">https://www.bseindia.com/xml-data/corpfiling/AttachLive/79ff5f5f-81a0-4bb0-a2f0-b93541f1164e.pdf</a>

Global

Dr. Reddy's Laboratories Forms New Subsidiary In Finland, 'Dr. Reddy's Finland Oy', As Step-Down Wholly-Owned Entity

6th National Domestic Violence Project in Europe Strengthens SuperCom's Position as a Leader in the Space
TEL AVIV, Israel, Dec. 23, 2024 /PRNewswire/ -- SuperCom (NASDAQ:&nbsp;SPCB),&nbsp;a global provider of secure solutions for the e-Government, IoT, and Cybersecurity sectors, announced today the successful launch of its new electronic monitoring (EM) project in Latvia. Following a competitive tender process, SuperCom was awarded this project, marking its third national contract in Latvia and further expanding its role in supporting the country's public safety efforts with the inclusion of domestic violence prevention.
Under this program, SuperCom is deploying its advanced PureSecurity EM Suite, featuring GPS tracking devices, secure communications, and real-time monitoring capabilities. SuperCom's technology will enhance the State Police of Latvia's ability to oversee offenders, enabling more effective prevention and response to domestic violence cases while bolstering regional public safety and security.

Contracts

SPCB

SuperCom Awarded New Domestic Violence Monitoring Project Using It's PureSecurity EM Suite, With The State Police Of Latvia

Benchmark analyst Bruce Jackson maintains Humacyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) with a Buy and raises the price target from $15 to $17.

Price Target

Analyst Ratings

HUMA

Benchmark Maintains Buy on Humacyte, Raises Price Target to $17

Despegar.com, Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DESP#NYSE">DESP</a>) shares are surging premarket on Monday after the company disclosed a <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42643653/despegar-com-enters-into-merger-agreement-to-be-acquired-by-prosus-for-19-50-per-share-in-cash" rel="noreferrer noopener">deal to be acquired</a> by Prosus for $19.50 per share in an all-cash transaction.
The transaction price reflects a 34% premium over Despegar&#8217;s 90-day volume-weighted average share price as of December 20, 2024.
Despegar&#8217;s Board of Directors has approved the merger agreement and recommended shareholder approval following the unanimous endorsement of a Transaction Committee composed of independent directors.
The deal values Despegar at approximately $1.7 billion in enterprise value.
Despegar will gain access to Prosus&#8217; extensive resources, operational expertise, and advanced AI capabilities.
As per the deal, a wholly owned subsidiary of Prosus will merge with Despegar, with Despegar remaining as the surviving entity.
Each outstanding share of Despegar will be converted into the right to receive $19.50 in cash, while the company&#8217;s Series A Preferred Shares will be canceled and converted into payments as specified by their terms.
The transaction is anticipated to close in the second quarter of 2025, pending shareholder approval, regulatory clearances, and other <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42643979/prosus-to-acquire-latin-americas-leading-online-travel-agency-despegar-for-us-1-7bn" rel="noreferrer noopener">customary closing conditions</a>.
Following the transaction&#8217;s completion, Despegar will transition to a privately held company. Its ordinary shares will be delisted from the New York Stock Exchange and will no longer trade on any public market.
Damian Scokin, Despegar&#8217;s CEO said, &#8221;Our customers will benefit from access to more services, enhanced customer experiences, increased loyalty benefits, and more comprehensive solutions tailored to their needs. Together we are setting the stage for a new era of travel marked by greater connectivity, innovation and value.&#8221;
Fabricio Bloisi, CEO of Prosus Group, added, &#8220;Despegar adds significantly to our strong ecosystem in Latin America, a market with amazing growth potential. Today&#8217;s announcement is about opportunity and growth &#8211; alone Despegar is a successful business with great fundamentals and a motivated management team; together, both Despegar and Prosus will make it even stronger.&#8221;
Investors can gain exposure to the DESP via Amplify ETF Trust Amplify Travel Tech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AWAY#NYSE">AWAY</a>) and Global X MSCI Argentina ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARGT#NYSE">ARGT</a>).
Price Action: DESP shares are up 32.80% at $19.45 premarket at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42643303" target="_blank" rel="noreferrer noopener">US Stocks To Open Higher As Wall Street Expects &#8216;Santa Rally&#8217; In Shortened Trading Week: MicroStrategy, Palantir, Qualcomm Among Stocks In Focus</a></li>
</ul>
Photo by Capri23auto from Pixabay

Equities

Mid Cap

ARGT

AWAY

DESP

Despegar To Be Acquired By Prosus For $1.7 Billion in All Cash Deal

<ul>
<li>TLRY</li>
<li>TSLA</li>
<li>AMD</li>
<li>NVDA</li>
<li>LUNR</li>
<li>PLTR</li>
<li>CORN</li>
<li>MSTR</li>
<li>KULR</li>
<li>QQQ</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

CORN

KULR

LUNR

MSTR

NVDA

PLTR

TLRY

TSLA

Top 10 Trending Stocks On WallStreetBets As Of December 23, 2024 (Via Swaggy Stocks)

On December 23, 2024, ReNew Energy Global Plc ("ReNew") announced the signing of definitive agreement to sell ReNew Sun Waves Private Limited ("RSWPL"), which houses a 300 MW operating solar asset to Anzen India Energy Yield Plus Trust ("Anzen"). The transaction is expected to close post completion of contractual obligations and conditions precedent including receipt of lender approval. Under the agreement, ReNew Private Limited, parent of RSWPL, will sell 100% shareholding and economic interest in RSWPL. The enterprise value determined under the agreement is ~$176 million&#x2A;, subject to net current assets and other such adjustments as provided in the definitive documents. Additionally, ~$17 million&#x2A; is expected to be received as an earn-out on account of change in law proceeds pertaining to increase in basic customs duty (BCD), safeguard duty (SGD) and goods &amp; service tax (GST), after the first payment is realised by RSWPL. The 300 MW SECI solar project is located in Jaisalmer, Rajasthan, and has been operational for ~3 years. The tariff for the 25-year power purchase agreement is INR 2.55/unit.

Asset Sales

ReNew Energy Global Announced Sale Of ReNew Sun Waves' 300 MW Solar Asset To Anzen India Energy Yield Plus For ~$176M; ~$17M Earn-Out Expected; The Tariff For The 25-Year Power Purchase Agreement Is INR 2.55/Unit

Benchmark analyst Michael Albanese reiterates Winnebago Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WGO#NYSE">WGO</a>) with a Buy and maintains $70 price target.

Reiteration

Benchmark Reiterates Buy on Winnebago Industries, Maintains $70 Price Target

Offerings

MGOL

MGO Global Prices Upsized $6M Public Offering Of 6.32M Units At $0.95 Per Unit; Includes Common Stock And Warrants Exercisable At $1.425 Pending Stockholder Approval; Closing Expected December 24, 2024

--Multi-year Agreement with ADT for Several Servicing Needs--
Spruce Power Holding Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPRU#NYSE">SPRU</a>) ("Spruce" or the "Company") today announced the first customer for its Spruce Pro servicing business. Spruce signed a multi-year Service Agreement with ADT, under which Spruce Pro will facilitate the management and resolution of workmanship and equipment warranty claims for customers of ADT's former solar business, which it wound down earlier in 2024.

Spruce Power Holding Corporation Class A Common Stock

SPRU

Spruce Power Announces Multi-Year Agreement With ADT For Several Servicing Needs Of ADT's Former Solar Business

Battle lines are drawn in <a href="https://www.benzinga.com/topic/defense">the defense sector</a>. On one side, Palantir Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) riding high on a meteoric stock surge of over 350% this year. On the other, defense titan Lockheed Martin Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>), grappling with sluggish stock performance and stiff competition from a rising tech consortium.
<h2 class="wp-block-heading">The Disruptor: Palantir</h2>
Palantir, alongside Anduril Industries, is leading <a href="https://www.benzinga.com//node/42640010">a groundbreaking coalition</a> with Elon Musk&#8216;s SpaceX and OpenAI to revolutionize the $850 billion U.S. defense market. The goal? Outpace traditional contractors by integrating AI-powered solutions and autonomous systems. 
Palantir's AI Platform already works seamlessly with Anduril&#8217;s Lattice software, signaling a shift toward modern, agile defense technologies.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="630" height="493" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23064119/Screenshot-2024-12-23-at-5.04.06-PM.png" alt="" class="wp-image-703970" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23064119/Screenshot-2024-12-23-at-5.04.06-PM.png 630w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23064119/Screenshot-2024-12-23-at-5.04.06-PM-300x235.png 300w" sizes="(max-width: 630px) 100vw, 630px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122324&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
Technically, PLTR stock is on a tear. Its share price of $80.55 is comfortably above the eight, 20 and 50-day simple moving averages (SMAs), signaling strong bullish momentum. However, with a relative strength index (RSI) of 70.81, it's entering overbought territory—a red flag for cautious investors.
Read Also: <a href="https://www.benzinga.com/trading-ideas/technicals/24/12/42620067/palantir-defies-gravity-army-deal-nasdaq-100-spotlight-fuel-rally">Palantir Defies Gravity: Army Deal, Nasdaq 100 Spotlight Fuel Rally</a>
<h2 class="wp-block-heading">The Titan: Lockheed Martin</h2>
Meanwhile, Lockheed is feeling the heat. 
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="630" height="493" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23064219/Screenshot-2024-12-23-at-5.04.17-PM.png" alt="" class="wp-image-703971" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23064219/Screenshot-2024-12-23-at-5.04.17-PM.png 630w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23064219/Screenshot-2024-12-23-at-5.04.17-PM-300x235.png 300w" sizes="(max-width: 630px) 100vw, 630px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122324&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
The defense giant's stock, at $489.02, is below key moving averages, including its 200-day SMA of $510.22, indicating bearish sentiment. A relative strength index (RSI) of 29.59 suggests the stock is oversold, leaving a sliver of hope for a bounce-back.
Despite its legacy status and deep-rooted Pentagon ties, Lockheed faces mounting pressure to adapt as rivals like Palantir challenge its dominance with innovative, cost-efficient technologies.
<h2 class="wp-block-heading">The Verdict</h2>
Palantir's agility and tech-first approach make it a compelling contender in a sector ripe for disruption. Lockheed, however, isn't out of the fight—its oversold status might attract value-driven investors betting on a rebound.
As the defense industry evolves, this tech-versus-tradition showdown is one stock battle investors can't afford to ignore. 
The question remains: Can Lockheed innovate fast enough to fend off Palantir's charge, or is this the dawn of a new era?
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/12/42643303/us-stocks-to-open-higher-as-wall-street-expects-santa-rally-in-shortened-trading-week-microstrategy-palantir-qualcomm-among-stocks-in-focus">US Stocks To Open Higher As Wall Street Expects &#8216;Santa Rally&#8217; In Shortened Trading Week: MicroStrategy, Palantir, Qualcomm Among Stocks In Focus</a></li>
</ul>
Image via Shutterstock

Long Ideas

Technicals

Tech

Palantir Vs. Lockheed: A Tech-Fueled Showdown In The $850 Billion Defense Market

Piper Sandler analyst Crispin Love maintains Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) with a Neutral and raises the price target from $168 to $179.

Piper Sandler Maintains Neutral on Blackstone, Raises Price Target to $179

WIIM

NUVB

Nuvation Bio shares are trading higher after the company announced the FDA accepted the New Drug Application for taletrectinib for the treatment of advanced ROS1+ NSCLC.

Anebulo Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANEB#NASDAQ">ANEB</a>), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid-induced toxicities (the "Company" or "Anebulo"), today announced a positive regulatory update and the close of a capital raise.
<ul>
<li>In a Phase 2 proof-of-concept study, Anebulo enrolled 134 adult subjects challenged with oral delta-9-tetrahydrocannabinoil ("THC"), oral selonabant blocked or reversed key CNS effects of THC, establishing the clinical path for intravenous selonabant for a much-needed targeted therapy for rapidly reversing the serious and life-threatening consequences of acute cannabis-induced toxicity in children</li>
<li>Anebulo met with FDA to discuss the development of intravenous selonabant and the initial plan for clinical testing</li>
<li>FDA acknowledged the unmet need for a treatment for children exposed to cannabis toxicity, and proposed a close, ongoing collaboration to efficiently advance the selonabant program for the pediatric indication</li>
<li>Anebulo plans to begin its Phase I SAD study of IV selonabant in healthy adults in 1H25</li>
<li>Anebulo entered into a definitive stock purchase agreement with 22NW, a company controlled by one of its directors, Nantahala Capital and an additional existing investor for the issuance and sale of 15.2 million shares of common stock for gross proceeds of $15 million in a private placement offering priced at-the-market under Nasdaq rules</li>
<li>In exchange for purchasing $10 million of shares of common stock in the private placement, Anebulo intends to modify the Loan and Security Agreement (LSA) that was entered into with 22NW and JFL Capital Management by reducing the maximum loan size to approximately $3 million, which reduces the LSA to just under the securitization threshold, and the removal of any securitization</li>
</ul>

Biotech

ANEB

Anebulo Pharmaceuticals Announces FDA Feedback For IV Selonabant To Address Cannabis-Induced Toxicity In Children And Completes $15M Capital Raise; Phase I Study Planned For 1H25

Chubb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>) has outperformed the market over the past 20 years by 2.05% on an annualized basis producing an average annual return of 10.3%. Currently, Chubb has a market capitalization of $109.65 billion. 
Buying $1000 In CB: If an investor had bought $1000 of CB stock 20 years ago, it would be worth $7,098.87 today based on a price of $272.01 for CB at the time of writing.
<h3>Chubb's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734963313_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

In the current session, Global Payments Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>) is trading at $111.71, after a 0.29% decrease. Over the past month, the stock fell by 4.62%, and in the past year, by 11.31%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2024/1734963307_0.png" alt="Past Year Chart" />

<h3>Comparing Global Payments P/E Against Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Global Payments has a lower P/E than the aggregate P/E of 46.95 of the Financial Services industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1734963307_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

P/E Ratio Insights for Global Payments

First Busey Corporation ("First Busey") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BUSE#NASDAQ">BUSE</a>), the holding company of Busey Bank, and CrossFirst Bankshares, Inc. ("CrossFirst") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFB#NASDAQ">CFB</a>), the holding company of CrossFirst Bank, today jointly announced that First Busey shareholders and CrossFirst shareholders have each voted to adopt and approve, as applicable, all proposals relating to the previously announced merger in which First Busey will acquire CrossFirst. The special shareholder meetings were held on Friday, December 20, 2024.

BUSE

First Busey And CrossFirst Bankshares Announce Each Co's Shareholder Approvals Of Merger

Benchmark analyst Robert Wasserman reiterates Ligand Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGND#NASDAQ">LGND</a>) with a Buy and maintains $135 price target.

LGND

Benchmark Reiterates Buy on Ligand Pharmaceuticals, Maintains $135 Price Target

Loop Capital analyst Mark Schappel maintains Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Buy and raises the price target from $185 to $205.

SNOW

Loop Capital Maintains Buy on Snowflake, Raises Price Target to $205

Intuitive Machines Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) shares are trading higher on Monday. The company announced that it secured additional contracts from NASA&#8217;s Near Space Network for <a href="https://www.benzinga.com/pressreleases/24/12/g42645401/intuitive-machines-expands-data-transmission-services-for-lunar-and-deep-space-missions">Direct-to-Earth services</a>.
What Happened: Intuitive Machines announced Monday morning that it received two new contract awards from NASA&#8217;s Near Space Network for subcategory 1.2 and subcategory 1.3. 
Subcategory 1.2 covers DTE Geostationary to Cislunar DTE Services, offering enhanced data transmission capabilities and autonomous operations. Subcategory 1.3 covers xCislunar DTE Services, addressing mission needs for highly elliptical orbits and deep space operations.
Both contracts are firm-fixed-price, indefinite-delivery/indefinite-quantity task orders designed to bolster NASA&#8217;s Lunar Exploration Ground Segment.&nbsp;
&#8220;We are privileged to help NASA deliver essential data and transmission services that support missions navigating the critical pathways between Earth, the Moon, and beyond. We believe these new awards complement our existing NSN contract and will expand our space communications and navigation service offerings,&#8221; said Steve Altemus, CEO of Intuitive Machines.
&#8220;They position us to capitalize on the&nbsp;$4.82 billion&nbsp;maximum potential value of the NSN contract, while supporting NASA&#8217;s Artemis campaign and commercial endeavors to expand the lunar economy.&#8221;
See Also: <a href="https://www.benzinga.com/general/space/24/12/42612382/spacex-to-launch-2-more-private-astronaut-missions-to-iss">SpaceX To Launch 2 More Private Astronaut Missions To ISS</a>
The contract awards come after NASA awarded Intuitive Machines a <a href="https://www.benzinga.com/news/24/09/40919566/intuitive-machines-stock-is-soaring-wednesday-whats-going-on">Near Space Network contract</a> for communication and navigation services related to subcategory 2.2 in September. 
Project timelines for these contracts span from February 2025 to September 2029, with an additional five-year option period that could extend contracts through September 2034.
LUNR Price Action: <a href="http://benzinga.com/quote/lunr">Intuitive Machines shares</a> were up 5.08% at $14.27 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: courtesy of Intuitive Machines.

Sports

Intuitive Machines Stock Is Moving Higher Monday: What's Going On?

Filing Form 10-K for the Year Ended June 30, 2024
Filing Form 10-Q for the Quarter Ending September 30, 2024
TAMPA, FL / ACCESSWIRE / December 23, 2024 / Upexi, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPXI#NASDAQ">UPXI</a>) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products, announced its financial results for the year ended June 30, 2024 and the first quarter ending September 30, 2024 last week. On November 20, 2024 the Company received written notice (the "Compliance Notice") from Nasdaq informing the Company that it has regained compliance with Nasdaq Listing Rule 5250( c)(1) (the "Rule"). The Staff had concluded that with the filing of these two periodic reports that the Company now complies with the Rule and accordingly these matters are now closed.

UPXI

Upexi Regains Compliance With NASDAQ Listing Standards

Bernstein analyst Luca Solca maintained a Hold rating on Birkenstock Holding plc (BIRK – Research Report) on December 17 and set a price target of ...

Bernstein Reaffirms Their Hold Rating on Birkenstock Holding plc (BIRK)

Analyst Edouard Aubin of Morgan Stanley maintained a Hold rating on Birkenstock Holding plc (BIRK – Research Report), with a price target of $58.00...

Balanced Growth and Valuation Concerns Lead to Hold Rating for Birkenstock Holding plc

Baird analyst Mark Altschwager raised the firm's price target on Birkenstock (BIRK) to $72 from $65 and keeps an Outperform rating on the shares po...

Birkenstock price target raised to $72 from $65 at Baird

BofA raised the firm's price target on Birkenstock (BIRK) to $70 from $65 and keeps a Buy rating on the shares. After Birkenstock reported a Q4 ear...

Birkenstock price target raised to $70 from $65 at BofA

Deutsche Bank raised the firm's price target on Birkenstock (BIRK) to $66 from $65 and keeps a Buy rating on the shares following the company's ear...

Birkenstock price target raised to $66 from $65 at Deutsche Bank

BMO Capital analyst Simeon Siegel raised the firm's price target on Birkenstock (BIRK) to $70 from $60 and keeps an Outperform rating on the shares...

Birkenstock price target raised to $70 from $60 at BMO Capital

Looking to 2025, Telsey expects consumer companies to experience low-single-digits to mid-single-digits sales growth on low-single-digit comparable...

Telsey names top picks for 2025

Goldman Sachs lowered the firm's price target on Birkenstock (BIRK) to $57.90 from $59.10 and keeps a Neutral rating on the shares. The company rep...

Birkenstock price target lowered to $57.90 from $59.10 at Goldman Sachs

JPMorgan spotlights 12 consumer names in its 'stocks for 2025' list

Birkenstock: Upside Is Not Attractive At The Current Valuation

ADDYY

AMZN

BBWI

BRCC

COST

CVNA

DKNG

FDIS

FSTA

POST

RSPD

RSPS

TSCO

WRBY

Earnings

Press Releases

Birkenstock Reports Record Second Quarter Revenue, up 23% Y/Y, Driven by Strong Consumer Demand Across All Segments, Channels and Categories; Company Raises Full-Year Revenue Growth Guidance to 20%

Events

Birkenstock Announces June Conference Participation

Birkenstock Announces Launch of Secondary Offering

Birkenstock Announced Pricing of $756 Million Secondary Offering of Ordinary Shares

Birkenstock Announces Third Quarter 2024 (Ended June 30, 2024) Results Date and Conference Call

Birkenstock Reports Record Third Quarter Revenue, up 19% Year-Over-Year, Driven by Continued Strong and Growing Consumer Demand

Birkenstock Announces September Conference Participation

Birkenstock Announces Fourth Quarter and Full Fiscal Year 2024 (Ended September 30, 2024) Results Date and Conference Call

Birkenstock Reports Fiscal 2024 Results: Revenue Growth and Adjusted EBITDA Ahead of Expectations

Allbirds

Crocs

Deckers Outdoor

Nike

Rocky Brands

Steven Madden

Skechers USA

Wolverine World Wide

BMO Capital

Baird

Deutsche Bank

Telsey Advisory Group

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 테바 파마수티컬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>)의 주식은 회사와 사노피 SA(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>)가 <a href="https://www.benzinga.com//node/42531132" target="_blank" rel="noreferrer noopener">궤양성 대장염 및 크론병</a>에 대한 두바키투그(Duvakitug)의 2b상 시험에서 1차 평가변수가 충족되었다고 발표한 후 주가는 33.88% 상승했다.
2. 클라비요(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVYO#NYSE">KVYO</a>)의 주식은 12.85% 급등했다.
3. 올리브 가든 모회사 다덴 레스토랑(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>)의 주식은 회사가 예상보다 좋은 2분기 EPS와 <a href="https://www.benzinga.com//node/42585797" target="_blank" rel="noreferrer noopener">2025 회계연도 매출 전망</a>을 발표한 후 12.54% 상승했다. 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/dri/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 상향 조정</a>했다.
4. 닥시미티(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>)의 주식은 10.91% 상승했다. 스티븐스 앤 컴퍼니(Stephens &amp; Co.)가 중립 등급으로 커버리지를 시작하고 <a href="https://www.benzinga.com/quote/docs/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 $55</a>로 제시했다.
5. 버켄스탁 홀딩(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>)의 주식은 회사가 예상보다 좋은 4분기 재무 결과와 2025 회계연도 가이던스를 발표한 후 9.70% 상승했다. 여러 애널리스트들이 <a href="https://www.benzinga.com//node/42599431" target="_blank" rel="noreferrer noopener">주가 전망을 상향 조정</a>했다.
6. 자빌(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>)의 주식은 회사가 예상보다 좋은 <a href="https://www.benzinga.com//node/42553094" target="_blank" rel="noreferrer noopener">1분기 EPS와 매출</a>을 발표한 후 7.30% 상승했다. 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/jbl/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 상향 조정</a>했다.
7. 뉴로크린 바이오사이언시스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>)의 주식은 6.88% 상승했다. FDA가 크레네시티(크리네서폰트, crinecerfont) 캡슐과 경구용 용액을 <a href="https://www.benzinga.com//node/42508449" target="_blank" rel="noreferrer noopener">부신피질호르몬 대체 요법 보조 치료제로 승인</a>했다. 이는 4세 이상의 성인 및 소아 환자의 선천성 부신 효소 결핍증(CAH) 치료에 사용된다.
8. 게임스탑(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>)의 주식은 지난 주 6.54% 상승했으며, 이는 3분기 실적의 강세가 지속된 결과이다.
9. 닥터 레디스 래버러토리스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDY#NYSE">RDY</a>)의 주식은 6.29% 상승했다.
10. 리 오토(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>)의 주식은 지난주 6.13% 상승했다.
사진 제공: Sundry Photography via Shutterstock

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
<ol>
<li>월그린스 부츠 얼라이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>)의 주가는 회사가 혼합된 3분기 실적을 보고하고 2024년 지침을 <a href="https://www.benzinga.com//node/39523397" target="_blank" rel="noreferrer noopener">컨센서스 추정치</a>보다 낮게 낮춘 후 24.12% 하락했다. 분석가들은 주식에 대한 <a href="https://www.benzinga.com/quote/wba/analyst-ratings" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">가격 예측</a>을 하향 조정했다.</li>
<li>플로어 앤 데코 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FND#NYSE">FND</a>)의 주식은 예상보다 나쁜 5월 주택판매 경제 데이터에 대한 반응으로 13.41% 급락했다.</li>
<li>모더나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)의 주가는 회사의 RSV 백신이 <a href="https://www.benzinga.com//node/39508239" target="_blank" rel="noreferrer noopener">50%의 효능을 보인</a> 이후 11.76% 급락했다.</li>
<li>버켄스탁 홀딩(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>)의 주식은 회사가 매각 주주가 최대 1,400만 주 보통주를 <a href="https://www.benzinga.com//node/39467369" target="_blank" rel="noreferrer noopener">공모</a>한다고 발표한 후 주가는 10.86% 하락했다.</li>
<li>베이진(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGNE#NASDAQ">BGNE</a>)의 주식은 지난주에 9.70% 하락했다.</li>
<li>풀 코퍼레이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POOL#NASDAQ">POOL</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/39484866" target="_blank" rel="noreferrer noopener">FY24 EPS 가이던스를 낮춘 </a>이후 9.19% 떨어졌다.</li>
<li>징동닷컴(JD닷컴)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>)의 주식은 미국이 <a href="https://www.benzinga.com//node/39521291" target="_blank" rel="noreferrer noopener">중국 기술에 대한 투자</a>를 억제하는 규정을 발표한 이후 8.89% 하락했다.</li>
<li>에코페트롤(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EC#NYSE">EC</a>)의 주식은 8.02% 급락했다</li>
<li>인터내셔널 페이퍼(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IP#NYSE">IP</a>)의 주식은 수자노(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUZ#NYSE">SUZ</a>)가 <a href="https://www.benzinga.com//node/39519611" target="_blank" rel="noreferrer noopener">인수 거래를 중단</a>하기로 한 이후 7.98% 하락했다.</li>
<li>마이크론 테크놀로지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>)의 주식은 지난 주 <a href="https://www.benzinga.com//node/39520174" target="_blank" rel="noreferrer noopener">3분기 실적과 4분기 전망</a>에 대한 정보가 나온 이후 7.62% 하락했다.</li>
</ol>
다음 기사 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/%eb%a6%ac%eb%b9%84%ec%95%88%ea%b3%bc-%ec%b9%b4%eb%b0%94%eb%82%98%eb%8a%94-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ea%b3%a0%ec%9d%98-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%9d%b8-10%eb%8c%80-%eb%8c%80/" target="_blank" rel="noopener">리비안과 카바나는 지난주 최고의 성과를 보인 10대 대형주 중 일부 (6월 23일-6월 29일)</a></li>
</ul>
촬영: Shutterstock의 Lutsenko_Oleksandr

지난주 이들 10개의 대형주는 최고의 성과를 거두었다. 이들 주식이 당신의 포트폴리오에 있나요?
<ol>
<li>버켄스탁 홀딩(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>)의 주가는 회사가 강력한 <a href="https://www.benzinga.com//node/39086620" target="_blank" rel="noreferrer noopener">2분기 실적을 발표</a>하고 연간 매출 성장 가이던스를 상향 조정한 후 22.20% 상승했다. 몇몇 애널리스트들은 <a href="https://www.benzinga.com/quote/birk/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 주가</a>를 상향 조정했다.</li>
<li>벌링턴 스토어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>)의 주식은 예상보다 나은 <a href="https://www.benzinga.com//node/39087376" target="_blank" rel="noreferrer noopener">1분기 실적</a>에 따라 21.47% 상승했다. 몇몇 분석가들은 <a href="https://www.benzinga.com/quote/burl/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 가격</a>을 상향 조정했습니다.</li>
<li>딕스 스포팅 굿즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>)의 주식은 회사가 1분기 실적을 <a href="https://www.benzinga.com//node/39061439" target="_blank" rel="noreferrer noopener">발표하고</a> 2024년 가이던스를 상향 조정한 후 21.34% 상승했다. 애널리스트들은 해당 주식의 <a href="https://www.benzinga.com//node/39071891" target="_blank" rel="noreferrer noopener">목표 주가</a>를 상향 조정했다.</li>
<li>베스트 바이(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>)의 주식은 2024년 1분기 <a href="https://www.benzinga.com//node/39084657" target="_blank" rel="noreferrer noopener">실적 발표 이후</a> 20.35% 상승했다. 주식의 목표 가격을 수정한 분석가는 거의 없다.</li>
<li>카바 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>)의 주식은 1분기 실적이 상회하고 2024회계연도 <a href="https://www.benzinga.com//node/39046904" target="_blank" rel="noreferrer noopener">가이던스</a>가 상향된 후 14.51% 상승했다. 몇몇 분석가들은 예측을 <a href="https://www.benzinga.com//node/39061653" target="_blank" rel="noreferrer noopener">상향</a> 조정했다.</li>
<li>니오(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>)의 주가는 12.06% 상승했다. 니오가 중국 전기 자동차 시장에서 입지를 계속 강화함에 따라 현재 이 회사의 <a href="https://www.benzinga.com//node/39094497" target="_blank" rel="noreferrer noopener">충전 네트워크</a>에는 상하이 자동차(SAIC Motor)의 EV 유닛 IM 모터스가 포함된 것으로 알려졌다.</li>
<li>HP(휴렛 팩커드)(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>)의 주식은 <a href="https://www.benzinga.com//node/39081876" target="_blank" rel="noreferrer noopener">2분기</a> 실적 발표 이후 11.62% 급등했다. 많은 분석가들은 주식에 대한 <a href="https://www.benzinga.com/quote/hpq/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 가격</a>을 높였다.</li>
<li>마라톤 오일(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRO#NYSE">MRO</a>)의 주식은 코노코필립스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>)가 이 회사를 <a href="https://www.benzinga.com//node/39095128" target="_blank" rel="noreferrer noopener">인수</a>하겠다고 발표한 후 주가는 11.51% 상승했다. 11.51% 상승했다.</li>
<li>랄프 로렌(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>) 주식은 9.77% 상승했다.</li>
<li>온 홀딩 AG(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>)의 주식은 트루이스트 증권(Truist Securities)의 분석가가 주식을 보류에서 매수로 <a href="https://www.benzinga.com//node/39042432" target="_blank" rel="noreferrer noopener">업그레이드</a>하고 목표 주가를 34달러에서 46달러로 높인 후 지난주 9.16% 상승했다.</li>
</ol>
다음 글도 읽어보기: <a href="https://kr.benzinga.com/news/%ec%84%b8%ec%9d%bc%ec%a6%88%ed%8f%ac%ec%8a%a4%ec%99%80-%ec%85%80%ec%8b%9c%ec%9a%b0%ec%8a%a4%eb%8a%94-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4/" target="_blank" rel="noopener">세일즈포스와 셀시우스는 지난주 최악의 성과를 보인 10개의 대형주 중 일부</a>
썸네일 사진=Shutterstock

Comments

Birkenstock Holding

뉴스

에 대한 최신 뉴스 Birkenstock Holding (NYSE:BIRK) 주식

일요일, 12월 22, 2024

일요일, 6월 30, 2024

일요일, 6월 02, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌